Healthcare
Live Price
Offline$609.94
+0.33% today
1Y Change
+20.09%
Window
Jun 20, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock with a market cap of $72.26B and listed on NASDAQ. The stock last traded around $609.94 and up 20.1% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +1.0%, EPS growth of +5.3%, a dividend yield of 0.5%. What stands out right now is revenue +1.0%, EPS +5.3%, free cash flow +11.3% with operating margin 24.3% and ROIC 8.5%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 16.5 and price/sales 4.8. Stock Foundry combines REGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REGN Max Drawdown
-26.05%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$16.1B
+32.0% YoY
FY Net Income
$8.1B
+86.1% YoY
Free Cash Flow
$6.5B
+47.6% YoY
Revenue Growth
+1.0%
EPS Growth
+5.3%
Gross Margin
84.5%
Net Margin
29.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14.3B | 14.2B | 13.1B | 12.2B | 16.1B |
| Gross Profit | 12.2B | 12.2B | 10.9B | 10.5B | 13.3B |
| Operating Income | 3.6B | 4.0B | 4.3B | 5.4B | 8.9B |
| EBITDA | 5.8B | 5.3B | 4.7B | 5.3B | 9.7B |
| Net Income | 4.5B | 4.4B | 4.0B | 4.3B | 8.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.1B | 2.5B | 2.7B | 3.1B | 2.9B |
| Total Assets | 40.6B | 37.8B | 33.1B | 29.2B | 25.4B |
| Total Liabilities | 9.3B | 8.4B | 7.1B | 6.6B | 6.7B |
| Shareholder Equity | 31.3B | 29.4B | 26.0B | 22.7B | 18.8B |
| Total Debt | 2.7B | 2.7B | 2.7B | 2.7B | 2.7B |
| Net Debt | -412M | 216M | -27M | -405M | -186M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7.1B
+41.2% YoY
Capital Expenditures
552M
+6.5% YoY
Free Cash Flow
6.5B
+47.6% YoY
Key ratios
Gross Margin
84.5%
Operating Margin
24.3%
Net Margin
29.6%
ROE
14.3%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.